Blue Light Cystoscopy With Cysview® Registry
Photocure
Summary
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Description
Data will be captured on specific patient types undergoing Blue Light Cystoscopy with Cysview for known or suspected non-muscle invasive bladder cancer. Specific clinical questions will be asked. 1. What is the incremental detection rate with Blue Light Cystoscopy with Cysview over conventional white light cystoscopy in each of the seven (7) patient populations? Does this translate into lower recurrence/progression rate? 2. How do the six (6) tumor variables used in the European Association of Urology (EAU) risk tables (primary/secondary, recurrence rate, size, multifocality, grade, and histo…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adult \>18 years old * Suspected or known non-muscle invasive bladder cancer on the basis of a prior cystoscopy Exclusion Criteria: * Porphyria * Gross hematuria * Known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives
Interventions
- DrugHexaminolevulinate hydrochloride (HCL)
Instillation in bladder
- DeviceKarl Storz D-Light C Photodynamic Diagnostic (PDD) system
Cystoscopy procedure
Locations (23)
- The University of Alabama at BirminghamBirmingham, Alabama
- Mayo ClinicPhoenix, Arizona
- USC/Norris Comprehensive Cancer CenterLos Angeles, California
- University of California Los AngelesLos Angeles, California
- VA Palo Alto Health Care SystemPalo Alto, California
- University of California, San FranciscoSan Francisco, California